Literature DB >> 16341806

Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures.

Anja Wagner1, Ingrid van Kessel, Mieke G Kriege, Carli M J Tops, Juul Th Wijnen, Hans F A Vasen, Conny A van der Meer, Iris I H van Oostrom, Hanne Meijers-Heijboer.   

Abstract

Hereditary non polyposis colorectal cancer (HNPCC) is a hereditary predisposition to colorectal and endometrial cancer, caused by mutations of the mismatch repair (MMR) genes MSH2, MLH1 and MSH6. Regular colonoscopy reduces the incidence of colorectal cancer in mutation carriers dramatically. The aim of this study was to evaluate the use of colonoscopy by proven HNPCC mutation carriers. We also evaluated the satisfaction with the counseling and screening procedures at the long term. A questionnaire survey was performed among 94 proven MMR gene mutation carriers. Data were analyzed using univariate and multivariate analysis. The average time of follow-up was 3,5 years (range 0.5-8.5 years). The response rate was 74%. The proportion of unaffected mutation carriers under colonoscopic screening increased from 31 to 88% upon genetic testing, and for gynecological screening from 17 to 69%. However, more than half of the responders experienced colonoscopy as unpleasant or painful. About 97% felt well informed during counseling, and 88% felt sufficiently supported. Ten percent of the responders reported a high cancer worry that was significantly (P = 0.007) associated with a high perceived cancer risk. Six responders (9%) regretted being tested. Remarkably, of 4 of these 6 a close relative died recently of cancer. Problems with obtaining a disability or life insurance or mortgage were experienced by 4 out 10 healthy carriers opting for these services. In conclusion, genetic testing for HNPCC considerably improves compliance for screening, which will result in a reduction of HNPCC-related cancer morbidity and mortality in mutation carriers. Most HNPCC gene mutation carriers cope well with their cancer susceptibility on the long term.

Entities:  

Mesh:

Year:  2005        PMID: 16341806     DOI: 10.1007/s10689-005-0658-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

1.  Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer.

Authors:  K Aktan-Collan; A Haukkala; J P Mecklin; A Uutela; H Kääriäinen
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

Review 2.  Colon cancer screening.

Authors:  R W Burt
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

3.  Personal theories of inheritance, coping strategies, risk perception and engagement in hereditary non-polyposis colon cancer families offered genetic testing.

Authors:  M McAllister
Journal:  Clin Genet       Date:  2003-09       Impact factor: 4.438

4.  Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer.

Authors:  M Miyaki; M Konishi; K Tanaka; R Kikuchi-Yanoshita; M Muraoka; M Yasuno; T Igari; M Koike; M Chiba; T Mori
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

5.  Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred.

Authors:  Y Akiyama; H Sato; T Yamada; H Nagasaki; A Tsuchiya; R Abe; Y Yuasa
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

6.  Psychological and behavioral implications of abnormal mammograms.

Authors:  C Lerman; B Trock; B K Rimer; A Boyce; C Jepson; P F Engstrom
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

7.  The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.

Authors:  Isis Dove-Edwin; Dominique Boks; Sheila Goff; Gemma G Kenter; Robert Carpenter; Hans F A Vasen; Huw J W Thomas
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

8.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.

Authors:  A Wagner; Y Hendriks; E J Meijers-Heijboer; W J de Leeuw; H Morreau; R Hofstra; C Tops; E Bik; A H Bröcker-Vriends; C van Der Meer; D Lindhout; H F Vasen; M H Breuning; C J Cornelisse; C van Krimpen; M F Niermeijer; A H Zwinderman; J Wijnen; R Fodde
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

9.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

Authors:  R Fishel; M K Lescoe; M R Rao; N G Copeland; N A Jenkins; J Garber; M Kane; R Kolodner
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

10.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

View more
  34 in total

1.  Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome.

Authors:  L H Katz; A M Burton-Chase; S Advani; B Fellman; K M Polivka; Y Yuan; P M Lynch; S K Peterson
Journal:  Clin Genet       Date:  2015-09-14       Impact factor: 4.438

2.  More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington's disease.

Authors:  Anette Hagberg; The-Hung Bui; Elisabeth Winnberg
Journal:  J Genet Couns       Date:  2010-09-28       Impact factor: 2.537

3.  Sharing genetic test results in Lynch syndrome: communication with close and distant relatives.

Authors:  Elena M Stoffel; Beth Ford; Rowena C Mercado; Darashana Punglia; Wendy Kohlmann; Peggy Conrad; Amie Blanco; Kristen M Shannon; Mark Powell; Stephen B Gruber; Jonathan Terdiman; Daniel C Chung; Sapna Syngal
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02-07       Impact factor: 11.382

4.  Balancing life with an increased risk of cancer: lived experiences in healthy individuals with Lynch syndrome.

Authors:  Helle Vendel Petersen; Mef Nilbert; Inge Bernstein; Christina Carlsson
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

5.  Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer.

Authors:  Cathrine Bjorvatn; Geir Egil Eide; Berit Rokne Hanestad; Nina Øyen; Odd E Havik; Anniken Carlsson; Gunilla Berglund
Journal:  J Genet Couns       Date:  2007-04       Impact factor: 2.537

6.  Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome.

Authors:  Elena M Stoffel; Rowena C Mercado; Wendy Kohlmann; Beth Ford; Shilpa Grover; Peggy Conrad; Amie Blanco; Kristen M Shannon; Mark Powell; Daniel C Chung; Jonathan Terdiman; Stephen B Gruber; Sapna Syngal
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

Review 7.  Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice.

Authors:  Kimberly A Kaphingst; Colleen M McBride
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

8.  Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer.

Authors:  Paul J Limburg; William S Harmsen; Helen H Chen; Steven Gallinger; Robert W Haile; John A Baron; Graham Casey; Michael O Woods; Stephen N Thibodeau; Noralane M Lindor
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-05       Impact factor: 11.382

9.  The Impact of Receiving Predictive Genetic Information about Lynch Syndrome on Individual Colonoscopy and Smoking Behaviors.

Authors:  Joanne Soo-Min Kim; Peter C Coyte; Michelle Cotterchio; Louise A Keogh; Louisa B Flander; Clara Gaff; Audrey Laporte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-15       Impact factor: 4.254

10.  Cancer genetic counselees' self-reported psychological distress, changes in life, and adherence to recommended surveillance programs 3-7 years post counseling.

Authors:  Afsaneh Hayat Roshanai; Richard Rosenquist; Claudia Lampic; Karin Nordin
Journal:  J Genet Couns       Date:  2009-02-11       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.